{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(1)"],"submitter":["Poubelle PE"],"funding":["Rare Disease Foundation","La Fondation du Grand défi Pierre Lavoie"],"pubmed_abstract":["<h4>Background</h4>Biological agents have allowed remarkable improvement in controlling autoimmune arthropathies, although none of the numerous biologics readily available represent a universal treatment standard. Moreover, classical and genetic predictors are currently unsatisfactory to predict individual response to a biologic, and the best treatment selection is still based on a trial-and-error approach. Here, we report a clinical case demonstrating the usefulness of examining the leukocytes' secretome of patients. We set up and standardized a protocol that examines a patient's immune responses to establish the secretome of the blood mononuclear leukocytes and personalize the biotherapy.<h4>Case presentation</h4>A 24-year-old woman was diagnosed with active early rheumatoid arthritis. T"],"journal":["Clinical and translational medicine"],"pagination":["19"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6548783"],"repository":["biostudies-literature"],"pubmed_title":["The use of leukocytes' secretome to individually target biological therapy in autoimmune arthritis: a case report."],"pmcid":["PMC6548783"],"pubmed_authors":["Sampaio Moura N","Tessier PA","Pelletier M","Poubelle PE","Page N","Longchamps MP","Beck DB","Aksentijevich I"],"additional_accession":[]},"is_claimable":false,"name":"The use of leukocytes' secretome to individually target biological therapy in autoimmune arthritis: a case report.","description":"<h4>Background</h4>Biological agents have allowed remarkable improvement in controlling autoimmune arthropathies, although none of the numerous biologics readily available represent a universal treatment standard. Moreover, classical and genetic predictors are currently unsatisfactory to predict individual response to a biologic, and the best treatment selection is still based on a trial-and-error approach. Here, we report a clinical case demonstrating the usefulness of examining the leukocytes' secretome of patients. We set up and standardized a protocol that examines a patient's immune responses to establish the secretome of the blood mononuclear leukocytes and personalize the biotherapy.<h4>Case presentation</h4>A 24-year-old woman was diagnosed with active early rheumatoid arthritis. T","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Jun","modification":"2025-05-18T11:18:36.949Z","creation":"2025-05-18T11:18:36.949Z"},"accession":"S-EPMC6548783","cross_references":{"pubmed":["31165299"],"doi":["10.1186/s40169-019-0236-7"]}}